Merck KGaA has completed the acquisition of the chromatography business of JSR Life Sciences, strengthening its downstream purification capabilities and expanding its portfolio for biopharmaceutical manufacturing.
The deal, executed through its U.S. and Canada life science arm MilliporeSigma, adds advanced Protein A chromatography technologies, including Amsphere Protein A resins, to its existing offerings. These technologies are critical for the purification of monoclonal antibodies, a key component in many modern biologic therapies.
By integrating these capabilities, the company aims to improve efficiency and scalability in downstream processing, helping pharmaceutical and biotech manufacturers accelerate production timelines and enhance reliability from early development through commercial-scale manufacturing.
The acquisition also brings a Belgium-based chromatography team of more than 50 employees into the organization. This team contributes technical expertise and application support, further strengthening the company’s ability to deliver end-to-end solutions for antibody purification and broader bioprocessing needs.
The chromatography business will be incorporated into the Process Solutions portfolio, which supports customers across the full spectrum of biopharmaceutical manufacturing.
Merck KGaA, Darmstadt, Germany operates globally across healthcare, life science, and electronics, with its life science division known as MilliporeSigma in the United States and Canada.
KEY QUOTE:
“This acquisition expands our downstream purification capabilities at a time when customers are pushing to scale biologics faster and more efficiently. With expanded Protein A offerings, we can help customers strengthen process consistency, support reliable manufacturing at scale, and ultimately accelerate access to critical therapies.”
Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany